期刊文献+

移植物抗宿主病与移植物抗白血病效应研究新进展 被引量:3

Development of research on graft-versus-host disease and graft-versus-leukemia
暂未订购
导出
摘要 异基因骨髓移植是治疗多种血液系统恶性肿瘤的有效方法,治疗效果主要归功于移植物抗白血病效应(graft-versus-leukemia,GVL),它可以清除残存肿瘤细胞,提高生存率。然而,GVL与骨髓移植的一大并发症——移植物抗宿主病(graft-versus-host disease,GVHD)紧密相连。现代科学研究揭示了急性GVHD的病理过程,在此过程中有一些机制发挥着抗肿瘤作用。曾经的观念认为,GVHD和GVL是相互关联、密不可分的,但最近的研究显示,虽然尚不能采取某种方式将这两者截然分开,但合理利用一些免疫细胞、细胞因子、信号通路、组织抗原,可以达到既降低GVHD又保留GVL的目的。 Allogeneic bone marrow transplantation(allo-BMT) is now an effective treatment for multiple maglinant hematological tumors. Graft-versus-leukemia (GVL) after allo-BMT can eliminate residual tumor cells and improve survivals, while it is closely related with severe graft-versus-host diseases(GVHD). Recent studies clarified the pathological changes of acute GVHD, being different from the old concepts. Now many scientists reached an agreement that although we can't separate GVHD and GVL completely, we can take some advantage of some immune cells, chemokines, cell signals, tissue antigens to reduce GVHD as well as remain GVL.
出处 《复旦学报(医学版)》 CAS CSCD 北大核心 2008年第5期779-781,785,共4页 Fudan University Journal of Medical Sciences
基金 上海市生物医药重大攻关课题(06ZD19013)
关键词 移植物抗宿主病 移植物抗白血病效应 抗原提呈细胞 自然杀伤细胞 调节T细胞 graft-versus-host diseases graft-versus-leukemia (GVL) antigen-presenting-cell (APC) naturalkiller cell(NK) regulatory T cell(Treg)
  • 相关文献

参考文献21

  • 1Cooke R,Gerbitz A, Crawtord JM, et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation[J]. J Clia Invest, 2001,11/7(12) : 1 581 - 1 589.
  • 2Hill GR, Teshima T, Gerbitz A, et al. Differential roles of IL-1 and TNF alpha on graft-versus-host disease and graft versus leukemia[J]. J Clin Invest, 1999,104(4) :459 - 67.
  • 3Couriel D,Saliba R, Hicks K, et al. Tumor necrosis factor-γ blockade for the treatment of acute GVHD[J]. Blood, 2004, 104:649- 654.
  • 4Duffner UA, Maeda Y, Cooke KR, et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease[J]. J hnmunol,2004,172:7 393 - 7 398.
  • 5Teshima T,Ordemann R, Reddy P,et al. Acute graft versus host disease does not require alloantigen expression on host epithelium[J]. Nature Medicine ,2002,8(6) :575 - 581.
  • 6Matte CC, Liu J, Cormier J ,et al. Donor APCs are required for maximal GVHD but not for GVL[J]. Nature Medicine ,2004, 111(9):987 - 992.
  • 7Anderson BE, Mcnff JM, Jain D, et al. Distinct roles for donor and host-derived antigen-presenting cells and co-stimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ[J]. Blood, 2005, 105 (5) :2 227 - 2 234.
  • 8Reddy P,Maeda Y, Liu C, et al. A crucial role for antigen- presenting cells and alloantigen expression in graft-versus- Leukemia responses[J]. Nature Medicine, 2005,11(11): 1 244-1 249
  • 9Ruggeri L,Capanni M,Casucci M,et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation[J]. Blood,2001,8(6):355-359.
  • 10Vanessa M Hubbard, Jeffrey M, et al. Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation[J]. Blood, 2005,106 : 3 285 - 3 292.

同被引文献36

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部